SCHLAP1 and prostate carcinoma: Furthermore, SChLAP1 overexpression inhibited miR-340-5p/miR-143-3p/miR-145-5p expression in prostate cancer cells, which were abrogated by treatments with EZH2, H3K27me3, and DNMT3a inhibitors (Fig. 4D–F).